Phase I study of irinotecan and temsirolimus in patients with refractory sarcomas.
S. Movva
No relevant relationships to disclose
T. Bocklage
No relevant relationships to disclose
B. Schmit
No relevant relationships to disclose
R. Quinn
No relevant relationships to disclose
B. J. Liem
No relevant relationships to disclose
C. F. Verschraegen
No relevant relationships to disclose